DNAnexus appointed Pieter De Leenheer as CTO and Todd Oakland as SVP and General Manager of Biopharma Business to accelerate AI innovation and business expansion.

The company initiated a targeted restructuring program that involved layoffs of 20 employees and plans for 35 new hires to pivot resources toward enterprise software growth.

The company was named to the 2026 Inc. 5000 list, recognizing its three-year revenue growth as one of the fastest-growing private companies in the U.S.

An in-depth look at how DNAnexus approaches the data infrastructure challenges in the life sciences industry, emphasizing the perspective that data state, rather than just model quality, is the primary hurdle for AI-driven drug discovery.

DNAnexus and Galatea Bio entered a strategic collaboration to manage and analyze genomic datasets of non-European origin to improve health equity.